Sotabase

Career

· Associate Professor, University of Tennessee2015–
· Assistant Professor, University of Tennessee2009–2015
· Postdoctoral Research Associate, University of Illinois at Urbana-Champaign2008–2009
· Ph.D., Computer Science, University of Illinois at Urbana-Champaign2005–2008
· Research Assistant, University of Illinois at Urbana-Champaign2005–2008
· Master, Computer Science, University of Virginia2002–2005
· Research Assistant, University of Virginia2002–2005

Publications (41)

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*
2010
452
cited
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial
2012
248
cited
Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension
2011
197
cited
The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure
2011
141
cited
Disposition Kinetics and Tolerance of Escalating Single Doses of Ramelteon, a High‐Affinity MT1 and MT2 Melatonin Receptor Agonist Indicated for Treatment of Insomnia
2006
137
cited
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
Gastroenterology · 2018
116
cited
Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring
2011
112
cited
Rapid Response to Vedolizumab Therapy in Biologic‐Naive Patients With Inflammatory Bowel Diseases
2019
89
cited
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis
Clinical Gastroenterology and Hepatology · 2020
63
cited
Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series
2016
59
cited
Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril
2013
49
cited
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery
2010
36
cited
Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis
2018
33
cited
Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome
2014
27
cited
Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial
2018
20
cited
Oral Antidiabetic Drugs: Bioavailability Assessment of Fixed‐Dose Combination Tablets of Pioglitazone and Metformin. Effect of Body Weight, Gender, and Race on Systemic Exposures of Each Drug
2007
19
cited
Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo‐controlled study
2017
18
cited
Adapting the Goal Attainment Approach for Major Depressive Disorder
2019
16
cited
Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus
2013
16
cited
Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies
2019
15
cited
Sotabase
Charles Cao | Researcher Profile | Sotabase | Sotabase